Skip to main content

NVO

Stock
Health Care
Biotechnology

Performance overview

NVO Price
Price Chart

Forward-looking statistics

Beta
0.72
Risk
40.18%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.

Company info

SectorHealth Care
IndustryBiotechnology
Employees62K
Market cap$636.4B

Fundamentals

Enterprise value$60.6B
Revenue$47.9B
Revenue per employee
Profit margin34.51%
Debt to equity85.70

Security info

ExchangeNyse American
Type of shareADR
Earnings per share (EPS)$3.71
Dividend per share$2.20
Revenue per share$68.14
Avg trading volume (30 day)$426M
Avg trading volume (10 day)$409M
Put-call ratio

Macro factor sensitivity

Growth-0.2
Credit+1.5
Liquidity-0.4
Inflation-1.7
Commodities-0.0
Interest Rates-0.9

Valuation

Dividend yield3.18%
PEG Ratio17.00
Price to sales1.04
P/E Ratio17.00
Enterprise Value to Revenue1.26
Price to book2.22

Upcoming events

Next earnings dayAugust 6, 2025
Next dividend day
Ex. dividend dayMarch 31, 2025

News

Weight loss drugs could be a gamechanger for women with a common hormonal disorder

Several women who have reported improvements in symptoms of polycystic ovary syndrome, a common hormonal disorder, after using GLP-1s such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Patients and some health experts view GLP-1s as a promising potential option for a condition that lacks a standard treatment and affects millions of women in the U.S.

CNBC (July 20, 2025)
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?

Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.

Zacks Investment Research (July 18, 2025)
Smart Money Going in Senior Health: Key Stocks in Elderly Care

RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.

Zacks Investment Research (July 11, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free